• Policy
• Patent protection for 42 yrs for Humira/32 yrs for Keytruda
• by Lee, Hye-Kyung May 16, 2023 09:07pm

• Policy
• Biopharmaceutical CDMO annual average of ↑31%
• by Lee, Hye-Kyung May 15, 2023 05:41am

• Policy
• Youkyung Oh was appointed as the first chairman of APFRAS
• by Lee, Hye-Kyung May 12, 2023 05:44am

• Policy
• HIRA plans to report on the re-evaluation
• by Lee, Tak-Sun May 12, 2023 05:44am

• Policy
• Triple-negative breast cancer tx Trodelbi approved in Korea
• by Lee, Hye-Kyung May 11, 2023 05:50am

• Policy
• ‘Pay more policy attention to advanced heart failures'
• by Hwang, byoung-woo May 11, 2023 05:49am

• Policy
• Rapidly changing breast cancer treatment
• by Choi, sun May 11, 2023 05:49am

• Policy
• A benefit study of the Gardasil 9 NIP is also forthcoming
• by Lee, Jeong-Hwan May 10, 2023 11:17pm

• Policy
• Prior HIRA approval is required to administer Crysvita
• by Lee, Tak-Sun May 10, 2023 06:00am

• Policy
• Insurance price ceiling reeval results to be notified soon
• by Lee, Tak-Sun May 9, 2023 05:38am